Health Canada
Santé Canada

STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: RVD-Hpα

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled	X
Not Controlled	☐

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance shows cannabinoid receptor agonist activity and must be included under item 1 of Schedule II to the CDSA.

Prepared by: _____ Date: _____
Zack Li

Verified by: _____ Date: _____
Mark Kozlowski

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: "third party information removed as per agreement with applicant"

Drug Status Report

Drug: RVD-Hpα

Drug Name Status: RVD-Hpα is the common name.

Chemical Name: Arg-Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His

Other Names: RVDPVNFKLLSH; RVD-hemopressin

Chemical structure: RVDPVNFKLLSH

Molecular Formula: $C_{65}H_{105}N_{19}O_{17}$

Pharmacological class / Application: Endogenous peptide

CAS-RN: N/A

International status:

US: RVD-Hpα is not listed specifically in the Schedules to the US *Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: RVD-Hpα is not listed in the schedules to the CDSA. The substance is an endogenous peptide found in the brain and has shown to demonstrate CB_1 receptor agonism in *in vivo* studies[1]. "Cannabis, its preparations, derivatives and similar synthetic preparations" are currently listed as item 1 in Schedule II to the CDSA. While there currently are not any peptides included under item 1 of Schedule II, RVD-Hpα can be synthesized and therefore be captured as a similar synthetic preparation. Given that RVD-Hpα does demonstrates cannabinoid receptor agonist activity, it must be included under item 1 of Schedule II to the CDSA.

Recommendation: RVD-Hpα is included in item 1 of Schedule II to the CDSA and is a controlled substance.

Date: June 7th, 2012.

[1]Gomes, I. et al. (2009) Novel endogenous peptide agonists of cannabinoid receptors, FASEB J. **23:** 3020-9